Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation (SGLT-2/PCOS)
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome
研究概览
地位
条件
详细说明
The study will be a randomized controlled clinical trial. Once the eligibility from screening visit is determined prior to baseline visit, randomization will be made by computer randomization for women who are admitted to Beni-Suef University Hospital. The Sample size will be 500 divided equally into 4 groups calculated with power=0.8.
Before initiation of the study, the population will be divided randomly into 4 equal groups: group A, B, C and D. The adjuvant therapy of each group will be group (A) Metformin , group (B) Dapagliflozin , Group(C) Combined Dapagliflozin-Metformin and group (D) with no adjuvant therapy (control group). The adjuvant therapy will be taken once daily with a main meal and started one month before initiation of letrozole. All groups will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
Ovulation rate (percentage of ovulatory cycles in the whole follow up period),Pregnancy rate (clinical pregnancy will be considered when an intrauterine gestational sac is seen and presence of a fetal heartbeat),Serum progesterone on day 21,Endometrial thickness at the time of ovulation and Weight, waist/hip ratio, height and body mass index (BMI) will be measured
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Banī Suwayf、埃及、62517
- Gynecology and Reproductive department in Beni-Suef University Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
Pre-menopausal women aged 20-40 with primary or secondary infertility and PCOS which render them unable to become pregnant. Diagnosis of PCOS will based on European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria, the diagnosis is made when at least two of the following criteria are met: oilgo and/or anovulation (infrequent or no ovulation), clinical and/or biochemical signs of hyperandrogenism including hirsutism, acne and/or increased testosterone levels or polycystic ovaries on ultrasound (defined as those containing at least 12 follicles measuring 2-9 mm in diameter arranged peripherally around an echo-dense stroma and/or with increased ovarian volume of at least 10 ml).
Exclusion Criteria:
Other causes of hyperandrogenism mimic PCOS such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen secreting tumors are excluded.
Persistent hyperprolactinemia, thyroid dysfunction defined as TSH < 0.2 mIU/ML or >5.5 mIU/mL) or patients with menopausal levels of FSH (> 15 mIU/mL) (A normal level within the last year is adequate for enter the study).
Liver disease is defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL, kidney disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL or significant anemia defined as Hemoglobin < 10 mg/dL.
Women with Type I or II diabetes mellitus who are poorly controlled (defined as a HA1c level > 7.0%).
Untreated poorly controlled hypertension is defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
Women who have undergone a bariatric surgery procedure in the recent past (<12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
Presence of any urinary symptom such as frequency, urgency, or bloody micturition.
In case of metabolic acidosis, osteoporosis, endometrial hyperplasia, or endometrial neoplasia.
Women who had gonadotropin induction, ovarian drilling before or women with hypergonadotropic hypogonadism or functional ovarian cysts (> 5cm).
Criteria of IVF/ICSI as poor Response, no Eggs or ectopic pregnancy. Women who receive antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas are likely to confound the effects of study medication or who are currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
Concomitant use of medication that could interfere with the absorption, metabolism, and excretion of drugs involved in the study as the use of Furosemide, cimetidine increase metformin concentration and nifedipine enhances the absorption of metformin.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:"metformin"
will take Metformin 1000mg as adjuvant therapy
|
will take Metformin 1000 mg once daily with a main meal and started one month before initiation of the first cycle of induction.
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
|
实验性的:"Dapagliflozin"
will take Dapagliflozin 10mg as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Dapagliflozin 10mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
实验性的:"Dapagliflozin-Metformin"
will take combined Dapagliflozin-Metformin 5/1000 as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Combined Dapagliflozin-Metformin 5/1000mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
其他:"control"
will take letrozole 2.5mg the no adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Ovulation rate
大体时间:"through study completion, an average of 1 year".
|
percentage of ovulatory cycles
|
"through study completion, an average of 1 year".
|
|
Pregnancy rate
大体时间:"through study completion, an average of 1 year".
|
when an intrauterine gestational sac is seen and presence of a fetal heartbeat)
|
"through study completion, an average of 1 year".
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum progesterone
大体时间:"through study completion, an average of 1 year".
|
Serum progesterone
|
"through study completion, an average of 1 year".
|
|
Endometrial thickness
大体时间:"through study completion, an average of 1 year".
|
Endometrial thickness
|
"through study completion, an average of 1 year".
|
|
Weight
大体时间:"through study completion, an average of 1 year".
|
Weight in kilogram
|
"through study completion, an average of 1 year".
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.